Margarita Maiak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Margarita Maiak has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anna Efremova
Research Centre for Medical Genetics, Moscow 115522, Russia
3 shared publications - Dmitry Vadimovich Goldshtein
Research Centre for Medical Genetics, Moscow 115522, Russia
3 shared publications - Tatiana Budagova
Research Centre for Medical Genetics, Moscow 115522, Russia
3 shared publications - Diana O. Mokrousova
Research Centre for Medical Genetics, Moscow 115522, Russia
2 shared publications - Asya Bastrich
Research Centre for Medical Genetics, Moscow 115522, Russia
1 shared publication
Latest Publications
- Open Access
Whole Tumor Cells and Their Derivatives for the Development of Therapeutic Cancer Vaccines
One approach to therapeutic cancer vaccine development uses whole tumor cells or their lysates as sources of a broad repertoire of tumor antigens. A key advantage of this strategy is that it does not require prior identification of tumor antigens, unlike personalized neoantigen peptide or mRNA vaccines, potentially reducing the time and cost of vaccine development. However, late-phase clinical trials have not demonstrated sufficient efficacy of tumor cell-based cancer vaccines. Currently, strategies to enhance the therapeutic potential of vaccines based on whole tumor cells and their derived lysates are being actively developed, and the vaccine potential of individual tumor cell components, such as cell membranes and extracellular vesicles, is under investigation. In this review, we systematize data on how whole tumor cells and their derivatives (lysates, cell membranes, and extracellular vesicles) are used to generate therapeutic cancer vaccines, analyze the results of experimental and clinical studies, and evaluate promising engineering and combination therapy strategies capable of overcoming the current limitations of this platform.
Open AccessWhole Tumor Cells and Their Derivatives for the Development of Therapeutic Cancer Vaccines
One approach to therapeutic cancer vaccine development uses whole tumor cells or their lysates as sources of a broad repertoire of tumor antigens. A key advantage of this strategy is that it does not require prior identification of tumor antigens, unlike personalized neoantigen peptide or mRNA vaccines, potentially reducing the time and cost of vaccine development. However, late-phase clinical trials have not demonstrated sufficient efficacy of tumor cell-based cancer vaccines. Currently, strategies to enhance the therapeutic potential of vaccines based on whole tumor cells and their derived lysates are being actively developed, and the vaccine potential of individual tumor cell components, such as cell membranes and extracellular vesicles, is under investigation. In this review, we systematize data on how whole tumor cells and their derivatives (lysates, cell membranes, and extracellular vesicles) are used to generate therapeutic cancer vaccines, analyze the results of experimental and clinical studies, and evaluate promising engineering and combination therapy strategies capable of overcoming the current limitations of this platform.
- Open Access
iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment
Adoptive T-cell therapy has demonstrated substantial clinical efficacy in several hematological malignancies, but autologous manufacturing remains limited by variability in starting cell material, manufacturing time, product heterogeneity, and T-cell dysfunction. Induced pluripotent stem cells (iPSCs) provide a potentially scalable and genetically engineerable source for the generation of standardized allogeneic T-cell products. This review summarizes current approaches to the differentiation of iPSCs into distinct T-cell phenotypes and evaluates their potential for cancer immunotherapy. We first discuss iPSC-derived conventional αβ T cells, including recent advances in feeder-free and scalable differentiation, maturation, and genetic engineering, as well as preclinical and early clinical evidence. We then examine γδ T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, focusing on their distinctive antigen-recognition mechanisms, effector functions, tissue tropism, differentiation strategies, and therapeutic applications. Across these populations, iPSC technology may facilitate standardized and scalable production while enabling targeted engineering of T-cell specificity and functional properties. However, important challenges remain, including efficient lineage-specific differentiation, maturation, phenotypic consistency, long-term persistence, tumor infiltration, and control of alloreactivity and immunogenicity. Overall, iPSC-derived T cells represent a versatile platform for developing diverse cellular immunotherapies, although their clinical potential remains dependent on further technological and translational advances.
Open AccessiPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment
Adoptive T-cell therapy has demonstrated substantial clinical efficacy in several hematological malignancies, but autologous manufacturing remains limited by variability in starting cell material, manufacturing time, product heterogeneity, and T-cell dysfunction. Induced pluripotent stem cells (iPSCs) provide a potentially scalable and genetically engineerable source for the generation of standardized allogeneic T-cell products. This review summarizes current approaches to the differentiation of iPSCs into distinct T-cell phenotypes and evaluates their potential for cancer immunotherapy. We first discuss iPSC-derived conventional αβ T cells, including recent advances in feeder-free and scalable differentiation, maturation, and genetic engineering, as well as preclinical and early clinical evidence. We then examine γδ T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, focusing on their distinctive antigen-recognition mechanisms, effector functions, tissue tropism, differentiation strategies, and therapeutic applications. Across these populations, iPSC technology may facilitate standardized and scalable production while enabling targeted engineering of T-cell specificity and functional properties. However, important challenges remain, including efficient lineage-specific differentiation, maturation, phenotypic consistency, long-term persistence, tumor infiltration, and control of alloreactivity and immunogenicity. Overall, iPSC-derived T cells represent a versatile platform for developing diverse cellular immunotherapies, although their clinical potential remains dependent on further technological and translational advances.
- Open Access
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment
CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells. In this paper, we analyze existing approaches to modifying CAR-NK cells and discuss the results of clinical trials involving CAR-NK therapies. Conventionally, approaches to NK cell modification can be divided into three main groups: strategies to enhance antitumor cytotoxicity, strategies to improve the survival of CAR-NK cells and prolong their persistence in the body, and strategies to increase the safety of CAR-NK cells. The effects of CAR-NK cells on different tumor types are presented, and the number of clinical trials involving CAR-NK cells has been increasing every year, with positive results so far. As of September 2025, all the trials are in the early 1–2 stages of research, and it is expected that the first CAR-NK product will be approved in the near future.
Open AccessStrategies for the Development of NK Cell-Based Therapies for Cancer Treatment
CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells. In this paper, we analyze existing approaches to modifying CAR-NK cells and discuss the results of clinical trials involving CAR-NK therapies. Conventionally, approaches to NK cell modification can be divided into three main groups: strategies to enhance antitumor cytotoxicity, strategies to improve the survival of CAR-NK cells and prolong their persistence in the body, and strategies to increase the safety of CAR-NK cells. The effects of CAR-NK cells on different tumor types are presented, and the number of clinical trials involving CAR-NK cells has been increasing every year, with positive results so far. As of September 2025, all the trials are in the early 1–2 stages of research, and it is expected that the first CAR-NK product will be approved in the near future.